Balanced news tone
News Sentiment
CELZ sentiment intelligence
Creative Medical Technology Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
50 relevant articles
Price is moving more forcefully than the current news tone suggests.
85/100 classification confidence.
directly relevant articles
high-authority source matches
-24.6% over one week, -58.0% over four weeks, trend inactive, and below fair value.
Creative Medical Technology (CELZ) plans big share boost and warrant approval
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
85/100 classification
One-week reaction
-24.6%
Price reacting lower
Trend fit
Trend inactive
-58.0% over four weeks
Fair value
-72.8%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
30
Negative
9
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
GlobeNewswire
Direct company coverage
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 13:15
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Creative Medical gets FDA clearance to add 15 patients in Olastrocel trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Stock Titan
Proactive
Direct company coverage
Creative Medical Technology opens nationwide burn-pit data registry
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 19:49
- Source
- Proactive
GlobeNewswire
Direct company coverage
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 13:00
- Source
- GlobeNewswire
DonanımHaber
Direct company coverage
Creative Medical Technology (CELZ) Slips 4.6% as Stock Approaches Key Support - Algorithmic Stock Picks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- DonanımHaber
dars.gov.et
Direct company coverage
Creative Medical Technology (CELZ) Edges Lower by 0.22% as Stock Consolidates Between Key Levels - Calendar Spread Trade
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- dars.gov.et
DonanımHaber
Direct company coverage
Creative Medical Technology Holdings (CELZ) Slips 1.3% as Stock Tests Key Support at $2.17 - Gap Up Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- DonanımHaber
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
GlobeNewswire
Direct company coverage
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Apr 2026 13:01
- Source
- GlobeNewswire
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Trefis
Direct company coverage
Day 6 of Gains Streak for Creative Medical Technology Stock with 43% Return (vs. 123% YTD) [10/27/2025]
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 27 Oct 2025 07:00
- Source
- Trefis
Zacks Investment Research
Direct company coverage
Should I buy Creative Medical Technology Holdings, Inc. (CELZ)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 31 Jul 2025 07:00
- Source
- Zacks Investment Research
Zacks Investment Research
Direct company coverage
What is the current Price Target and Forecast for Creative Medical Technology Holdings, Inc. (CELZ)
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 29 Jul 2022 00:34
- Source
- Zacks Investment Research
TradingView
Direct company coverage
CELZ Stock Price and Chart — NASDAQ:CELZ
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Mar 2022 07:00
- Source
- TradingView